Researchers evaluated the efficacy of dextromorphan-bupropion among patients with major depressive disorder and comorbid anxiety.
Your search for major depressive disorder returned 51 results
Click on a filter below to refine your search. Remove a filter to broaden your search.
Researchers searched for protective effects in gut microbiota from the pathogenesis of major depressive disorder.
For this study, community-dwelling adults were evaluated for major depressive disorder, generalized anxiety disorder, and global sleep quality over an 18 year period.
Patients with somatoform disorders, major depressive disorder, and healthy controls were recruited between 2016 and 2017 at the Ambulante Psychosoziale Rehabilitation in Austria and Schoen Clinic Roseneck in Germany.
This prospective, multi-center, open-label trial, CAN-BIND-1 was conducted between 2012 and 2017.
Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.
AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.
Researchers compared grey matter volume patterns in adult patients with attention-deficit/hyperactivity disorder and bipolar disorder.
Researchers compared the white matter networks of patients with remitted major depressive disorder and remitted bipolar disorder to find disease-specific alterations.
A cross-sectional family study sought to determine if parents’ transmission of anxiety is sex specific.